A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

NCT00001052 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

110

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: Aluminum hydroxide
BIOLOGICAL: QS-21
BIOLOGICAL: rgp120/HIV-1MN

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)